Aptitude Medical Systems
Aptitude Medical Systems, founded in 2011 in Goleta, California, developed the Metrix platform — a palm-sized molecular diagnostics system delivering lab-quality PCR results in 15-30 minutes for consumers, healthcare providers, employers, and global health programs.
- Company typePrivate
- Founded2011
- HeadquartersGoleta, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Aptitude Medical Systems does
Aptitude Medical Systems, founded in 2011 and headquartered in Goleta, California, is a deep-tech healthcare company that has developed the Metrix platform — a palm-sized molecular diagnostics system that delivers laboratory-quality PCR results in 15-30 minutes without requiring traditional PCR instrumentation. The underlying technology combines nucleic acid amplification testing with proprietary electrochemical aptamer-based sensing, Multi-Parameter Particle Display (MPPD) for high-throughput aptamer discovery, and machine learning-guided aptamer refinement published in Nature Communications (2021). The platform consists of a reusable Metrix Reader (priced at $34.95, rated for over 1,000 tests, with Bluetooth and WiFi connectivity) and a menu of single-use test cartridges, currently anchored by the Metrix COVID-19 Test ($24.95) and the Metrix COVID/Flu multiplex test. Pipeline products include an STI panel for chlamydia, gonorrhea, and trichomoniasis, and a Filovirus Panel for Ebola and Marburg viruses. Reported clinical performance is 98% sensitivity and 99% specificity for nasal swab samples and 91% sensitivity and 99% specificity for saliva samples, with no presumptive-negative limitation requiring follow-up lab confirmation.
The company serves four primary customer segments. Individual consumers purchase tests through a direct ecommerce storefront (shop.aptitudemedical.com) launched in September 2023 and Amazon.com launched in October 2023. Healthcare providers — including urgent care centers, physician offices, and hospitals — buy through a SEKISUI Diagnostics channel partnership (signed January 2024) for U.S. point-of-care distribution and through direct enterprise field sales for orders exceeding 100 tests or 20 readers. Employer and organization customers use the platform for workplace and event screening, and global health organizations in low- and middle-income countries access the STI and Filovirus panels through Gates Foundation- and BARDA-funded programs. Revenue mechanics follow a razor/blade model: the durable Reader is sold at a low price point with a 1-year warranty, while recurring revenue is generated by higher-margin consumable cartridges across multiple test types. The company maintains a lowest-default-price philosophy and avoids seasonal promotions.
Aptitude's commercial profile is shaped by an unusually grant-heavy capital structure: cumulative non-dilutive funding exceeds $124M across awards from BARDA (including up to $53.7M in April 2023 plus $9M and $8.25M in July 2025), the Bill & Melinda Gates Foundation (over $10M for the STI program), and NIH RADx, with only a $1M early-stage TSVC round in 2013 disclosed. The FDA granted Emergency Use Authorization for the Metrix COVID-19 Test in October 2022 — the world's first saliva and nasal swab-based OTC molecular test without physician supervision — followed by FDA authorization for the COVID/Flu multiplex test in February 2025. Headcount sits in the 11-50 range, with active hiring across research, customer insights, and scientific communications roles.
Aptitude Medical Systems firmographics
Firmographics- Name
- Aptitude Medical Systems
- Legal name
- Aptitude Medical Systems, Inc.
- Website
- https://aptitudemedical.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Aptitude Medical Systems, founded in 2011 in Goleta, California, developed the Metrix platform — a palm-sized molecular diagnostics system delivering lab-quality PCR results in 15-30 minutes for consumers, healthcare providers, employers, and global health programs.
- Ownership category
- akta.pro rank
Aptitude Medical Systems industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)
Keywords
Where Aptitude Medical Systems is headquartered
LocationHeadquarters
- HQ city
- Goleta
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aptitude Medical Systems business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Consumable test kit sales: Revenue from sale of single-use Metrix test kits (e.g., $24.95 per Metrix COVID-19 test kit) used with the reusable Metrix Reader. Multiple test types in pipeline including COVID/Flu, STI panel, Strep, Filovirus, and avian flu.
- Metrix Reader (durable instrument): Revenue from sale of reusable Metrix Reader ($34.95), a durable palm-sized diagnostic device that lasts for over 1,000 tests and is compatible with all current and future Metrix test kits. Sold separately from test kits.
- Enterprise/bulk test kit sales: Volume pricing for enterprise customers with demand exceeding 100 tests or recurring large orders. Custom purchasing terms, technical support, and warranty offerings available through sales team ([email protected]).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Single Metrix COVID-19 Test kit |
| One time/ perpetual license | Pay-as-you-go | Metrix Reader (reusable instrument) |
| Unit Pricing | Pay-as-you-go | Metrix COVID-19 Test & Reader Bundle |
| Unit Pricing | Multi-year contract | Enterprise / large volume orders |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Aptitude Medical Systems product offering
Product offeringCore offering
Aptitude Medical Systems designs, manufactures, and sells the Metrix molecular diagnostics platform, a palm-sized device paired with single-use test cartridges that deliver lab-quality PCR results in 15–30 minutes from saliva, nasal swab, blood, or urine samples. The platform is sold over-the-counter to consumers and through healthcare providers and enterprise customers, with the FDA-authorized COVID-19 and COVID/Flu tests commercially available and an STI panel and filovirus panel in development.
Product overview
Aptitude Medical Systems offers the Metrix® platform, a next-generation molecular diagnostics system that brings lab-quality PCR testing to point-of-care and home settings. The platform consists of the reusable Metrix® Reader device and a growing menu of single-use test cartridges. Current products include the FDA-authorized Metrix® COVID-19 Test (the first OTC molecular test with dual sample capability for saliva or nasal swab), the Metrix® COVID/Flu multiplex test, and the Metrix® Reader. The pipeline includes the Metrix® STI Panel (CT/NG/TV) for sexually transmitted infection detection and the Metrix® Filovirus Panel for Ebola and Marburg viruses. The platform is designed for scalability across respiratory, sexual health, and infectious disease applications.
Differentiator
Problem solved
Functional benefit
Brands
- Metrix: Next generation molecular diagnostics platform that delivers lab-quality PCR results in 15-30 minutes in a palm-sized device. Used for Point of Care and Over-the-Counter testing.
Products and services
- Metrix COVID-19 Test FDA Emergency Use Authorized molecular diagnostic test for detection of SARS-CoV-2 that works with both saliva and nasal swab samples, delivering PCR-quality results in 30 minutes or less for at-home over-the-counter and point-of-care use.
- Metrix COVID/Flu Test FDA-authorized multiplex molecular test detecting SARS-CoV-2, Influenza A, and Influenza B for point-of-care and over-the-counter use, delivering PCR-quality results in approximately 20 minutes.
- Metrix Reader Reusable palm-sized diagnostic device that reads Metrix test sensors with Bluetooth and WiFi connectivity, designed for durability of 1,000+ tests, eco-friendly with minimal disposables, and compatible with all current and future Metrix tests.
Quantifiable outcome
- Nasal swab sensitivity: 98% / specificity: 99%; Saliva sensitivity: 91% / specificity: 99% (no 'presumptive negative' limitation)
- +3 more outcomes
Companies that use Aptitude Medical Systems
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Aptitude Medical Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature8 records
Aptitude Medical Systems partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and supporting.
- SEKISUI DiagnosticscorePartnership with SEKISUI Diagnostics for U.S. commercialization of the Metrix COVID-19 test, expanding distribution to point-of-care and home test markets. SEKISUI Diagnostics is leveraging its established diagnostic distribution network to broaden Metrix product availability.
- eMedsupportingDr. Michael Mina (CSO of eMed, former Harvard professor) served as a key thought partner and advocate for the Metrix platform, providing external validation of the home molecular diagnostics vision and public health impact potential in news coverage and industry commentary.
Scale indicators7 records
Recent moves6 records
Expansion highlights9 records
Aptitude Medical Systems competitors and assessment
Company assessmentBroad incumbents
- Cepheid (Danaher): Cepheid's GeneXpert system is the dominant molecular point-of-care platform globally, offering PCR-quality results in clinical settings. Comparable to Aptitude's Metrix in technology (NAAT/PCR) and target market (POC infectious disease), though Cepheid operates at much larger scale and requires substantial capital equipment investment.
- Abbott Diagnostics: Abbott's ID NOW and Binax NOW dominate U.S. point-of-care and OTC diagnostics. Aptitude competes with Abbott on POC economics (PCR quality vs. antigen) and on retail shelf space at Amazon and pharmacy chains.
- Roche Diagnostics (Cobas Liat): Roche's Cobas Liat is a compact, rapid PCR system used in urgent care and pharmacy settings for Strep A, Flu, RSV, and COVID. Directly comparable on POC molecular menu and clinical workflow integration, though at a different price point and instrument footprint.
- bioMérieux (BioFire): BioFire's FilmArray multiplex syndromic panels (respiratory, GI, meningitis/encephalitis) set the standard for POC multiplex molecular diagnostics. Comparable to Aptitude's syndromic panel ambition and target customer base of urgent care and hospital labs.
- QuidelOrtho: QuidelOrtho offers Sofia rapid antigen and molecular diagnostics for POC settings. Overlaps with Aptitude on respiratory POC market and on the urgent care customer segment where Aptitude is positioning Metrix.
Direct peers
- Cue Health: Cue Health developed a direct-to-consumer and clinical molecular testing platform (Reader + cartridge) for respiratory and sexual health. Closely comparable to Aptitude on form factor, OTC positioning, and reader-plus-consumable business model, and serves as the most direct U.S. competitor in home molecular diagnostics.
- Visby Medical: Visby Medical makes a palm-sized, single-use PCR device for infectious disease testing (STI panel, COVID) without separate instrumentation. Directly comparable to Metrix in miniaturization ambition and POC molecular target menu, particularly relevant for Aptitude's STI panel roadmap.
- Lucira Health (now part of Pfizer): Lucira developed one of the first FDA-authorized OTC molecular COVID-19 tests (Lamp technology) before being acquired by Pfizer. Comparable to Aptitude as a direct OTC molecular peer, illustrating both the commercial potential and the capital-intensity challenges of the category.
Emerging players
- Talis Biomedical: Talis developed a cartridge-based molecular diagnostic platform targeting POC infectious disease and women's health. Comparable emerging peer on platform approach and target test menu, providing a reference point for Aptitude's commercial-stage valuation.
Others
- Mesa Labs (now part of Sotera Health / Accuratus Lab Services): Mesa Labs/Accuratus provides contract testing and laboratory analytical services, including diagnostic test validation. Relevant as a comparable for Aptitude's QC and release testing activities supporting regulatory submissions and clinical validation work.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Aptitude Medical Systems social profiles
Digital presenceAptitude Medical Systems compliance and trust
Trust signalCompliance2 records
Aptitude Medical Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aptitude Medical Systems leadership team
Management profileNumber of profiles
Profiles4 records
Aptitude Medical Systems funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aptitude Medical Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aptitude Medical Systems
What does Aptitude Medical Systems do?
Aptitude Medical Systems designs, manufactures, and sells the Metrix molecular diagnostics platform, a palm-sized device paired with single-use test cartridges that deliver lab-quality PCR results in 15–30 minutes from saliva, nasal swab, blood, or urine samples. The platform is sold over-the-counter to consumers and through healthcare providers and enterprise customers, with the FDA-authorized COVID-19 and COVID/Flu tests commercially available and an STI panel and filovirus panel in development.
Is Aptitude Medical Systems a public or private company?
Aptitude Medical Systems is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Aptitude Medical Systems founded?
Aptitude Medical Systems was founded in 2011. It employs 11 to 50 people.
Where is Aptitude Medical Systems based?
Aptitude Medical Systems is headquartered in Goleta, United States, in the North America region.
How does Aptitude Medical Systems make money?
Three revenue lines are on record. Consumable test kit sales are the primary driver. The others are metrix Reader (durable instrument) and enterprise/bulk test kit sales.
Who are Aptitude Medical Systems's main competitors?
Broad incumbents on record are Cepheid (Danaher), Abbott Diagnostics, Roche Diagnostics (Cobas Liat), bioMérieux (BioFire) and QuidelOrtho. Direct peers are Cue Health, Visby Medical and Lucira Health (now part of Pfizer). Talis Biomedical is listed as an emerging player. Mesa Labs (now part of Sotera Health / Accuratus Lab Services) is listed as an others.
Does Aptitude Medical Systems have an API?
No public API is recorded for Aptitude Medical Systems.
What industry is Aptitude Medical Systems in?
Aptitude Medical Systems's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.